Certara

CERT

Market cap $954M

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

Cerrado Gold Inc. (CERT:CA) Q4 2025 Earnings Call Transcript

Certara, Inc. (CERT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Certara, Inc. (CERT) Presents at Leerink Global Healthcare Conference 2026 Transcript

Certara, Inc. (CERT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix®).

The Touchstone Small Cap Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell 2000® Index, for the quarter ended December 31, 2025. The best performing stocks based on relative performance vs. the benchmark during the quarter included White Mountains Insurance Group, Revolve Group Inc. and Haemonetics Corp. The more challenged positions based on relative performance during the quarter included NewMarket Corp., Certara Inc., and Gates Industrial Corp plc.

RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

Certara, Inc. (CERT) Q4 2025 Earnings Call Transcript

Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.15 per share a year ago.